Associate Professor at Ramon y Cajal University Hospital, Madrid, Spain
Adelaida Lamas Ferreiro has built a distinguished career in pediatric pulmonology with a focus on cystic fibrosis and infectious respiratory diseases. Throughout her professional timeline, her pioneering efforts in the study and application of Antibiotic therapies have made significant impacts on clinical outcomes. Her leadership in both hospital settings and international consortia has cemented her role in optimizing Antibiotic use in cystic fibrosis care. She has evaluated Antibiotic efficiency in respiratory complications and promoted Antibiotic stewardship in pediatric medicine. With more than 50 clinical trials and academic projects centered on Antibiotic strategies, Adelaida’s research continuously reinforces Antibiotic relevance in managing chronic pulmonary conditions, particularly within vulnerable pediatric populations requiring advanced Antibiotic interventions.
Professional Profile
Google Scholar
Education
Adelaida Lamas holds a Ph.D. in Medicine and Surgery from Universidad Autónoma de Madrid with academic excellence in pediatric sedation monitoring. Her postgraduate qualifications include a master’s degree in pulmonology unit management and another in clinical hospital administration. From early stages, her education was deeply influenced by studies on Antibiotic action in pulmonary systems. She has pursued extensive training on Antibiotic pharmacodynamics, pharmacokinetics, and Antibiotic mechanisms of resistance. Her international clinical rotations emphasized Antibiotic treatment in cystic fibrosis, reinforcing her expertise in tailoring Antibiotic protocols. Her educational path consistently aligned with evolving Antibiotic research, translating her academic groundwork into high-impact Antibiotic clinical methodologies.
Experience
Dr. Adelaida Lamas has held numerous clinical roles from pediatrician to consultant specialist in cystic fibrosis and pediatric pulmonology. Over three decades, she has directly engaged in Antibiotic regimen development, Antibiotic response analysis, and inpatient/outpatient Antibiotic monitoring. She has collaborated on national Antibiotic protocols and served as a senior advisor for pediatric Antibiotic clinical trials. She spearheaded multidisciplinary teams addressing Antibiotic efficacy in chronic lung infections. Her long-standing presence at the Ramón y Cajal University Hospital included management of patients under high-risk Antibiotic therapies. Her career reflects an unwavering commitment to maximizing Antibiotic utility through evidence-based approaches, influencing global Antibiotic practices.
Research Interest
Adelaida’s research focuses primarily on cystic fibrosis, pediatric lung diseases, and the development of advanced Antibiotic protocols. Her investigative work has examined the influence of inhaled and systemic Antibiotic agents on microbial resistance, with a special interest in Pseudomonas aeruginosa and MRSA strains. She has evaluated biofilm formation suppression using tailored Antibiotic therapies. Her publications address therapeutic challenges posed by Antibiotic resistance in CF patients. Additionally, she explores Antibiotic rotation strategies and novel delivery systems for pediatric populations. Her evolving research underscores Antibiotic relevance in chronic infection modulation, driving forward pediatric pulmonary care innovations via adaptive Antibiotic strategies.
Awards and Honors
Throughout her career, Adelaida has received national and international recognition for her work in Antibiotic research. She was awarded for her contributions to improving Antibiotic application in cystic fibrosis treatment. Her doctoral thesis earned the “Dra. Juana Román First Prize” for excellence in pediatric medicine and Antibiotic safety analysis. She served as principal advisor in the Spanish national Antibiotic positioning reports. As a respected voice in Antibiotic advisory boards and task forces, she influenced policy-making and regulatory evaluations of pediatric Antibiotic use. Her honors reflect a profound contribution to scientific understanding and clinical integration of Antibiotic therapies in respiratory medicine.
Research Skills
Adelaida’s skill set includes designing, conducting, and supervising Antibiotic trials and interventions for pediatric lung diseases. She employs techniques to evaluate Antibiotic resistance, optimize dosage, and analyze pharmacological responses. Her work integrates bioinformatics, molecular diagnostics, and microbiological cultures to assess Antibiotic impact in real time. She is adept in critically appraising clinical literature on Antibiotic therapy and translating findings into bedside protocols. Her proficiency in ethical evaluation of Antibiotic use in vulnerable groups is evident from her role in national ethics committees. These multidisciplinary capabilities solidify her role as a leader in Antibiotic clinical innovation and translational application.
Publications
-
Title: Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey
Authors: P. Mondejar-Lopez, E. Quintana-Gallego, R.M. Giron-Moreno, et al.
Journal: Respiratory Medicine, Vol. 170, Article 106062, 2020
-
Title: Insulin resistance, β-cell dysfunction and differences in curves of plasma glucose and insulin in the intermediate points of the standard glucose tolerance test in adults with cystic fibrosis
Authors: M.C. Megías, O.G. Albarrán, P.G. Vasco, A.L. Ferreiro, L.M. Carro
Journal: Endocrinología y Nutrición (English Edition), Vol. 62(2), Pages 91–99, 2015
-
Title: A comprehensive evaluation of omega-3 fatty acid supplementation in cystic fibrosis patients using lipidomics
Authors: Ó. Pastor, P. Guzmán-Lafuente, J. Serna, M. Muñoz-Hernández, A.L. Neyra, et al.
Journal: The Journal of Nutritional Biochemistry, Vol. 63, Pages 197–205, 2019
-
Title: Protocol for the diagnosis and follow up of patients with cystic fibrosis
Author: S. Gartner
Journal: Anales de Pediatría (Barcelona, Spain: 2003), Vol. 71(3), Pages 250–264, 2009
-
Title: Tolerance of two inhaled hypertonic saline solutions in patients with cystic fibrosis
Authors: L.M. Carro, A.L. Ferreiro, M.R. de Valbuena Maiz, C.W. Struwing, G.G. Álvarez, et al.
Journal: Medicina Clínica, Vol. 138(2), Pages 57–59, 2012
Conclusion
Adelaida Lamas remains an influential force in pediatric medicine, with her legacy deeply rooted in Antibiotic innovation. Her strategic insights and practical applications of Antibiotic therapies have improved care standards, particularly for cystic fibrosis patients. Her work bridges academic excellence and clinical precision, ensuring Antibiotic efficacy against evolving microbial threats. She is recognized not only for her scientific achievements but also for her mentorship in Antibiotic clinical research. Her enduring contributions ensure the continual advancement of Antibiotic science, affirming its central role in child health and respiratory care. Adelaida’s lifelong dedication to Antibiotic research sets a benchmark for future medical leaders.